BiotechTubeBiotechTube
Home/Dystrogen Therapeutics/Maria Siemionow
MS

Maria Siemionow

Founder, Chief Scientific Officer

Dystrogen Therapeutics

Therapeutic Areas

Muscular DystrophyNeuromuscular DiseasesRare DiseasesSarcopeniaNeurodegenerative Diseases

Dystrogen Therapeutics Pipeline

DrugIndicationPhase
DT-DEC01Duchenne Muscular Dystrophy (DMD)Phase 1
DT-200Neuro-Degenerative DiseasePreclinical
DT-201SarcopeniaPreclinical
DT-202Age related muscle lossPreclinical

Leadership Team at Dystrogen Therapeutics

KS
Kris Siemionow
Co-Founder, Chief Executive Officer
PL
Paul Lewicki
Co-Founder, Board Member
View full Dystrogen Therapeutics profile